This interventional pilot study (n=4; target n=5) tests a single oral microdose (30 mg ayahuasca alkaloids co-formulated with l‑epicatechin complex) in healthy adults aged 25–60 to assess blood neurotransmitters, IL-6, safety, and mood.
Single-group, open-label, non-randomised pilot in healthy volunteers assessing a single morning oral microdose of ayahuasca alkaloids (30 mg) co-administered with an l‑epicatechin cyclodextrin complex; biological samples collected at baseline and 1.5 hours post-dose.
Primary measures include blood cholinesterase and IL-6 at baseline and 1.5 hours post-intervention, along with safety observations and mood/self-efficacy assessments.
Single oral microdose of ayahuasca alkaloids co-formulated with l‑epicatechin cyclodextrin complex.
Dissolved in water and propylene glycol in 50 mL bottle; taken in the morning.
l‑epicatechin equivalent from 1.31 g cyclodextrin complex (210 mg l‑epicatechin).